A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Pancreas Cancer.

Cytologically or pathologically verified diagnosis of pancreatic adenocarcinoma; locally advanced or distant metastatic disease that is not surgically curable. Pts who have had prior surgery for pancreas cancer must be at least 2 wks beyond surgery and recovered from all effects of surgery. Pts with partial resections of the stomach and duodenum as part of primary therapy for pancreatic cancer are eligible. Cases with major resection of the small intestine are not eligible. Pts who have undergone pancreaticoduodenectomy as part of primary therapy for pancreatic cancer are eligible. Pts may not have received prior chemotherapy, hormonal therapy, immunotherapy, radiation or chemoradiotherapy as neoadjuvant or adjuvant treatment or as treatment for advanced pancreas cancer. Radiation for palliation to metastatic sites is allowed. Pts must be able to swallow and/or receive enteral medications, no concurrent use of proton inhibitors, no brain metastases. No plans for the pts to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy.